Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

44.54 -0.58 (-1.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 861,826
Open 44.95
Bid (Size) 38.25 (1)
Ask (Size) 49.75 (20)
Prev. Close 45.12
Today's Range 44.10 - 45.94
52wk Range 29.16 - 45.94
Shares Outstanding 53,145,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Unpacking Q2 Earnings: Elanco (NYSE:ELAN) In The Context Of Other Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Elanco (NYSE:ELAN) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
2 Healthcare Stocks on Our Watchlist and 1 We Avoid
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID... 
Via StockStory
Topics Stocks

Performance

YTD
+22.3%
+22.3%
1 Month
+20.2%
+20.2%
3 Month
+38.2%
+38.2%
6 Month
+40.7%
+40.7%
1 Year
+28.3%
+28.3%

More News

Read More
Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q2
Via StockStory
Topics Artificial Intelligence Intellectual Property
Earnings Scheduled For August 5, 2025
Via Benzinga
Supernus Pharmaceuticals to Participate in September Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Branded Pharmaceuticals Stocks Q2 Recap: Benchmarking Bristol-Myers Squibb (NYSE:BMY)
Via StockStory
Topics Artificial Intelligence Intellectual Property
1 Unpopular Stock That Deserves a Second Chance and 2 Facing Headwinds
Via StockStory
2 Safe-and-Steady Stocks to Target This Week and 1 We Brush Off
Via StockStory
Integer Holdings, Astrana Health, Surgery Partners, IQVIA, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know
Via StockStory
Topics Economy
1 Small-Cap Stock with Competitive Advantages and 2 We Brush Off
Via StockStory
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Fits the Affordable Growth Strategy with Strong Fundamentals and Attractive Valuation
Via Chartmill
Q2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Winners And Losers Of Q2: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Branded Pharmaceuticals Stocks Q2 In Review: Merck (NYSE:MRK) Vs Peers
Via StockStory
Topics Artificial Intelligence Intellectual Property
Clover Health, Surgery Partners, Illumina, Bruker, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know
Via StockStory
Topics Economy
SUPN Q2 Deep Dive: Growth Drivers Shift to New Portfolio as Legacy Products Fade
Via StockStory
1 Momentum Stock for Long-Term Investors and 2 Facing Challenges
Via StockStory
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX)
Via StockStory
Topics Artificial Intelligence Intellectual Property
Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today
Via StockStory
Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales
Via StockStory
Supernus Announces Second Quarter 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals (SUPN) Reports Earnings Tomorrow: What To Expect
Via StockStory
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today
Via StockStory
Topics Lawsuit
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Supernus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Supernus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Supernus Pharmaceuticals, Inc. - Common Stock trade on?
Supernus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock is SUPN on the Nasdaq Stock Market
What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?
The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 44.54
When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 09/02/25 04:00 PM ET
What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 2.37B
How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?
Supernus Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.